VIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden
Click Here to Manage Email Alerts
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA, speaks about 4D-150, a novel intravitreally administered gene therapy for wet age-related macular degeneration.
“We all like genetic treatment that is given intravitreally and does not necessitate subretinal therapy,” she said.
In the phase 2 PRISM trial, a single injection of 4D-150 (4D Molecular Therapeutics) given to patients previously treated with multiple anti-VEGF injections was able to reduce the treatment burden by almost 90%.
“It is very promising for our patients to have a treatment that will be able to [stabilize their] disease without the need for extremely frequent injections,” Loewenstein said.
Collapse
Loewenstein A. Update on gene therapy for neovascular AMD. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Click Here to Manage Email Alerts